In the immunocompetent population with DLBCL, CD30 positivity defines a histology with improved survival, however, the characteristics and outcomes of ARL treated HIV (+) tumors expressing CD30 are not well studied. The gene discussed is TNFRSF8; the disease is diffuse large B-cell lymphoma.